Natixis Adma Biologics, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding ADMA
# of Institutions
312Shares Held
184MCall Options Held
917KPut Options Held
91.6K-
Black Rock Inc. New York, NY18.6MShares$300 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.1MShares$291 Million0.01% of portfolio
-
State Street Corp Boston, MA13MShares$209 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.6MShares$203 Million0.05% of portfolio
-
Morgan Stanley New York, NY8.6MShares$138 Million0.01% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.16B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...